CLAIMS

What is claimed is:

1. Use of a Dihydropyrazino-Pyrazine Compound in combination with MDV3100 in the manufacture of a medicament for treating a prostate cancer, wherein the Dihydropyrazino-Pyrazine Compound is 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, or isotopologue thereof.

2. The use of claim 1, wherein the prostate cancer is relapsed or refractory prostate cancer.

3. The use of claim 1, wherein the prostate cancer is castration-resistant prostate cancer.

4. The use of claim 1, wherein the prostate cancer is an E-twenty six (ETS) overexpressing prostate cancer.

5. The use of claim 1, wherein the prostate cancer is metastatic castration-resistant prostate cancer.